The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...
Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular acce ...
Key Takeaways The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and ...
EndoTheia announced today that it completed the first-in-human clinical trial for its FlexStone basket, a steerable kidney ...
Approximately 16% of the global population, or about 890 million people, suffer from obesity. The World Health Organization ...
The FDA granted fast track designation to ALE.P02, an antibody-drug conjugate targeting Claudin-1 (CLDN1), for use in ...
Does it work? Does it cause any side effects? For each clinical trial, study organizers must follow a plan, known as a protocol. A protocol describes exactly what happens during the study, and ...
The National Institutes of Health (NIH) has unveiled a new artificial intelligence (AI) algorithm designed to more ...
The World Institute of Kimchi(WIKIM) has announced that the regular consumption of kimchi, a traditional Korean fermented ...
A recent discussion with BDO's clinical trials editor and Audrey Davis of CSC, discussed strategies to increase clinical ...
Discover how inebilizumab reduces flares and improves remission rates in IgG4-related disease in this phase 3 clinical trial.
A patient with small cell lung cancer shared her clinical trial experience with CURE® and how she encourages other patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback